NAD+ and the Problem With Giving Cells the Molecule They Need

First, an honest clarification that a lot of catalogue copy skips: NAD+ is not a peptide. It is a dinucleotide coenzyme. It sits in this catalogue because it belongs to the same research conversation, not because it belongs to the same chemical class.

With that established, NAD+ is one of the more mechanistically interesting molecules in metabolic research, and the difficulty of raising it inside a cell is a genuinely instructive problem.

What NAD+ actually does

Nicotinamide adenine dinucleotide operates in two distinct capacities, and conflating them causes confusion:

• As a redox carrier. Cycling between NAD+ and NADH, it shuttles electrons through glycolysis, the TCA cycle and oxidative phosphorylation. In this role it is regenerated, not consumed.
• As a consumed substrate. Sirtuins, PARPs and CD38 cleave NAD+ and consume it. This role is why the pool can be depleted at all.

The second role is where the ageing literature focuses. Sirtuin activity is NAD+-dependent, PARP activation during DNA damage response draws heavily on the pool, and CD38 expression rises with age. All three trend toward depletion over time.

The bioavailability problem

Here is the part that makes NAD+ research awkward. The intact molecule does not readily cross the plasma membrane. Extracellular NAD+ is largely degraded to nicotinamide riboside or nicotinamide before anything enters the cell, meaning much of what is administered is not taken up as NAD+ at all.

This is why most of the serious literature works with precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — which use identified transport routes and salvage pathways. Studying NAD+ directly means confronting the delivery question head-on rather than assuming it away.

Where the evidence is strongest and weakest

The strongest evidence is mechanistic and preclinical: NAD+ decline with age is well documented across tissues and species, and restoring it in model organisms produces measurable effects on mitochondrial function.

The weakest link is translation. Human trials of precursors have reliably raised blood NAD+ markers; demonstrating that this produces the downstream functional outcomes seen in animal models has been considerably harder. That gap is the honest state of the field.

Practical notes

• NAD+ is light- and moisture-sensitive and degrades faster in solution than most lyophilised peptides. Reconstitute close to use.
• Solution pH matters. NAD+ is unstable in alkaline conditions; degradation accelerates noticeably above neutral.
• Assay for the compartment you care about. If your hypothesis is about sirtuin activity, an extracellular measurement is not the readout.

The salvage pathway

Cells rarely build NAD+ from scratch. De novo synthesis from tryptophan exists but contributes modestly in most tissues. The bulk of the pool is maintained by the salvage pathway, which recycles nicotinamide — the product of NAD+ consumption — back into NAD+.

The rate-limiting step is NAMPT, which converts nicotinamide to nicotinamide mononucleotide. NAMPT expression and activity therefore constrain how much NAD+ a cell can maintain, and NAMPT declines with age in several tissues. This is why the field's attention sits on precursors and on NAMPT itself rather than on NAD+ delivery: the pathway, not the molecule, is usually the bottleneck.

CD38, inflammation and the consumption side

Depletion is not only a synthesis problem. CD38, an NAD+-consuming ectoenzyme, increases with age and with inflammatory signalling, and is now regarded as a major driver of the age-related decline.

That reframes the question usefully. If consumption is rising rather than synthesis falling, then supplying more substrate addresses a symptom while the underlying draw continues. It also predicts that CD38 inhibition and precursor supplementation should interact — a prediction that has held up in several preclinical reports and is among the more testable propositions in this area.

Measuring NAD+ honestly

Measurement is where a great deal of NAD+ research goes wrong, because the molecule is unstable and compartmentalised.

• Extraction chemistry matters. NAD+ and NADH have opposite pH stability — NAD+ degrades under alkaline conditions, NADH under acidic. A single extraction cannot preserve both, which is why the NAD+/NADH ratio is harder to measure well than either alone.
• Quench fast. The pool turns over in minutes. Slow sample handling measures your handling, not your biology.
• Whole-cell lysate averages compartments. Mitochondrial, nuclear and cytosolic pools are regulated separately; a lysate number is a weighted average that may not move even when the compartment you care about does.
• Cycling assays are convenient and non-specific. LC-MS is the more defensible method where the claim is quantitative.

Handling

• Reconstitute immediately before use. NAD+ in solution degrades appreciably faster than most peptides in this catalogue.
• Keep it out of alkaline buffers. Degradation accelerates sharply above neutral pH.
• Protect from light, and store lyophilised material desiccated and cold.

Edit Labs supplies NAD+ with a published certificate of analysis for every lot. For research use only.